Binance Labs invests in BIO Protocol to revolutionize decentralized science

Source Cryptopolitan

Binance Labs, the crypto exchange’s venture capital arm, has invested in decentralized science (DeSci) by backing the BIO Protocol. This accelerator is designed to help early-stage scientific research startups access decentralized funding opportunities.

BIO Protocol expands its BioDAO network

BIO Protocol promotes a network of Biotech Decentralized Autonomous Organizations (BioDAOs), which form communities to fund, develop, and co-own innovative pharmaceuticals and therapies. According to Binance Labs, BioDAOs solve gaps in traditional funding for rare diseases, longevity research, and emergent health concerns.

The details of the investment’s exact amount were not disclosed, but it will enable BIO Protocol to grow its network by providing seed funding for new projects and strengthening community and tokenomics support. Binance Labs’ Investment Director Andy Chang commented:

“BIO Protocol represents a significant step forward in DeSci by merging biotechnology and DeFi. At Binance Labs, we are dedicated to unlocking groundbreaking advancements that drive long-term, real-world impact by supporting projects building meaningful technology.”

~Andy Chang

Binance Labs has more than 200 projects in its portfolio, most of which contribute to the development of decentralized finance. However, some involve gaming, artificial intelligence, and other sectors. For instance, Binance Labs supports Pluto Studio, which established the popular tap-to-earn Telegram mini-app Catizen.

Binance Labs and BIO Protocol to support IP-driven DAOs

BIO Protocol’s network of eight BioDAOs had a market capitalization of $200 million in November 2023. As co-founder of the Molecule platform, BIO Protocol’s Paul Kohlhaas introduced intellectual property non-fungible tokens (IP-NFTs). The protocol supports the sale of IP-NFTs.

One of BIO Protocol’s cornerstone projects, longevity-focused VitaDAO, was founded in 2021. In February 2023, it obtained $4.1 million in funding from pharmaceutical manufacturer Pfizer and supported the launch of Matrix Biosciences in October.

According to Binance Labs, the protocol’s next batch will feature projects to find a cure for Long COVID and rare diseases and build quantum microscopes to examine quantum biological processes.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
October hike odds climb toward 60% as Goldman and BofA both flip — what Warsh's "dose of accommodation" really changedRate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.
Author  Irene Q.
Sep 23, Wed
Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.
placeholder
Four jobs reports in five days: what JOLTS, ADP, claims and the September payrolls mean for the October Fed decisionThe US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.
Author  Mitrade
Sep 28, Mon
The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.
placeholder
RBA set to hike interest rate to 4.60% in September as inflation remains elevatedThe Reserve Bank of Australia (RBA) is widely expected to raise the Official Cash Rate (OCR) by 25 basis points (bps) to 4.60% from 4.35% on Tuesday, after keeping rates unchanged at its previous two meetings
Author  FXStreet
Yesterday 01: 40
The Reserve Bank of Australia (RBA) is widely expected to raise the Official Cash Rate (OCR) by 25 basis points (bps) to 4.60% from 4.35% on Tuesday, after keeping rates unchanged at its previous two meetings
placeholder
Nvidia's $150 billion buyback landed — and the AI sector fell anyway. That's the signal worth tradingNvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.
Author  Irene Q.
21 hours ago
Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.
placeholder
The 30-year Treasury just hit a 22-year high — and the bond market is not pricing the Fed, it is pricing the deficitThe 30-year Treasury yield closed at 5.56% on 28 September, the highest since June 2004, while the 10-year reached 5.24% and the 20-year 5.60%. The curve has steepened roughly 30bp in eight sessions even as October hike odds sit at 70.3%. That gap is the story: the long end is repricing fiscal and inflation risk, not policy. With PCE on Wednesday and payrolls on Friday, here is what the long end is really saying.
Author  Irene Q.
20 hours ago
The 30-year Treasury yield closed at 5.56% on 28 September, the highest since June 2004, while the 10-year reached 5.24% and the 20-year 5.60%. The curve has steepened roughly 30bp in eight sessions even as October hike odds sit at 70.3%. That gap is the story: the long end is repricing fiscal and inflation risk, not policy. With PCE on Wednesday and payrolls on Friday, here is what the long end is really saying.
goTop
quote